Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets
作者： Holly Meany , Brigitte C. Widemann , Nancy Ratner
DOI: 10.1007/978-3-642-32864-0_29
关键词:
摘要: Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is only successful treatment for MPNST, and outcome unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals NF1, because prognosis NF1-associated appears to be worse than that sporadic tumors, many studies have used NF1 models comparisons between MPNST. Currently, molecular analyses preclinical testing beginning aid identification promising therapies target these neoplasms. Knowledge epidemiology, clinical presentation, diagnosis, prognostic factors anticipated allow earlier detection of, more for,
springer.com
elsevier.com
sci-hub.st 参考文章(146)
Helen P. Kourea, Irene Orlow, Bernd W. Scheithauer, Carlos Cordon-Cardo, James M. Woodruff, Deletions of the INK4A Gene Occur in Malignant Peripheral Nerve Sheath Tumors but not in Neurofibromas American Journal of Pathology. ,vol. 155, pp. 1855- 1860 ,(1999) , 10.1016/S0002-9440(10)65504-6
Miriam A. Bredella, Martin Torriani, Francis Hornicek, Hugue A. Ouellette, William E. Plamer, Ziv Williams, Allan J. Fischman, Scott R. Plotkin, Value of PET in the assessment of patients with neurofibromatosis type 1. American Journal of Roentgenology. ,vol. 189, pp. 928- 935 ,(2007) , 10.2214/AJR.07.2060
Jilong Yang, Antti Ylipää, Yan Sun, Hong Zheng, Kexin Chen, Matti Nykter, Jonathan Trent, Nancy Ratner, Dina C Lev, Wei Zhang, None, Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment Clinical Cancer Research. ,vol. 17, pp. 7563- 7573 ,(2011) , 10.1158/1078-0432.CCR-11-1707
Kemal Kosemehmetoglu, Julie A Vrana, Andrew L Folpe, TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Modern Pathology. ,vol. 22, pp. 872- 878 ,(2009) , 10.1038/MODPATHOL.2009.47
S J Miller, Z D Lan, A Hardiman, J Wu, J J Kordich, D M Patmore, R S Hegde, T P Cripe, J A Cancelas, M H Collins, N Ratner, Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis Oncogene. ,vol. 29, pp. 368- 379 ,(2010) , 10.1038/ONC.2009.360
C. Gregorian, J. Nakashima, S. M. Dry, P. L. Nghiemphu, K. B. Smith, Y. Ao, J. Dang, G. Lawson, I. K. Mellinghoff, P. S. Mischel, M. Phelps, L. F. Parada, X. Liu, M. V. Sofroniew, F. C. Eilber, H. Wu, PTEN dosage is essential for neurofibroma development and malignant transformation Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 19479- 19484 ,(2009) , 10.1073/PNAS.0910398106
James Reynolds, Millie Whatley, Ambereen Kurwa, Maria Tsokos, Wanda Salzer, Andrea Gillespie, Andrea Baldwin, Joanne Derdak, Brigitte Widemann, Holly Meany, Eva Dombi, 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatric Blood & Cancer. ,vol. 60, pp. 59- 64 ,(2013) , 10.1002/PBC.24212
Kathleen A. Leppig, Paige Kaplan, David Viskochil, Molly Weaver, June Ortenberg, Karen Stephens, Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. American Journal of Medical Genetics. ,vol. 73, pp. 197- 204 ,(1997) , 10.1002/(SICI)1096-8628(1997)73:2<197::AID-AJMG17>3.0.CO;2-P
K. S. Vogel, Mouse Tumor Model for Neurofibromatosis Type 1 Science. ,vol. 286, pp. 2176- 2179 ,(1999) , 10.1126/SCIENCE.286.5447.2176
Vincent M. Moretti, Eileen A. Crawford, Arthur P. Staddon, Richard D. Lackman, Christian M. Ogilvie, Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. American Journal of Clinical Oncology. ,vol. 34, pp. 417- 421 ,(2011) , 10.1097/COC.0B013E3181E9C08A